NCT07607275招募中4 期
Effect of the Traditional Chinese Medicine Yufeng Ningxin in Patients With Hypertension: a Randomized, Double-blind, Placebo-controlled Trial
Beijing Anzhen Hospital16 个研究点 分布在 1 个国家目标入组 350 人开始时间: 2026年5月15日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 350
- 试验地点
- 16
研究概览
简要总结
Yufeng Ningxin, a traditional Chinese medicine, has demonstrated potential antihypertensive effects in animal studies and small clinical trials, but has not yet been rigorously evaluated in large randomized clinical trials. Here, the investigators conducted a double-blind, randomized controlled trial to assess the efficacy and safety of Yufeng Ningxin tablets in patients with hypertension.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female participants aged 18-65 years;
- •Newly diagnosed, untreated hypertension or treated hypertension with a seated systolic blood pressure of 140-159 mmHg and a daytime mean ambulatory systolic blood pressure ≥135 mmHg, following a ≥2-week washout of background antihypertensive medications;
- •The patient is capable of understanding the study requirements, is willing and able to comply with study procedures, and has provided written informed consent.
排除标准
- •Secondary hypertension (including, but not limited to, renovascular hypertension, pheochromocytoma, primary aldosteronism, Cushing syndrome, aortic coarctation, or due to known history of moderate-to-severe obstructive sleep apnea);
- •Orthostatic hypotension (symptomatic or asymptomatic);
- •Participation in another hypertension-related clinical trial at enrollment or within 6 months prior;
- •Currently taking, taken within 30 days prior to randomization, or anticipated to receive during the study treatment period any medication or herbal supplement known to significantly affect blood pressure (with the exception of medications for the treatment of essential hypertension). These drugs include, but are not limited to: organic nitrates, glucocorticoids (excluding topical or inhaled corticosteroids), central nervous system stimulants (e.g., methylphenidate, dexmethylphenidate, amphetamines), estrogens, monoamine oxidase inhibitors, digitalis preparations, Chinese proprietary medicines (such as Tianma Gouteng Granules, Songling Xuemaikang Capsules, Yangxue Qingnao Granules), and herbal medicines (including Salvia miltiorrhiza, Uncaria rhynchophylla, Ginkgo biloba leaves, Prunella vulgaris, etc.);
- •Users of prescription non-steroidal anti-inflammatory drugs (NSAIDs); initiation of, changes to, or discontinuation of sodium-glucose co-transporter (SGLT2) inhibitor therapy within 4 weeks prior to screening. Patients who were stably taking an SGLT2 inhibitor or low-dose aspirin (defined as ≤100mg per day) for at least 4 weeks prior to screening with no anticipated changes during the study are permitted;
- •Severe hepatic or renal diseases (ALT >3 times the upper limit of normal value, or end stage renal disease on dialysis, or eGFR <30 mL/min/1.73 m2);
- •Type 1 diabetes or poorly controlled type 2 diabetes (HbA1c>9.0%);
- •History of large atherosclerotic cerebral infarction or hemorrhagic stroke (not including lacunar infarction and transient ischemic attack [TIA]);
- •Hospitalization for myocardial infarction within last 6 months; Coronary revascularization (PCI or CABG) within last 12 months; Planned for PCI or CABG in the next 6 months;
- •Sustained atrial fibrillation or arrhythmias interfering with electronic BP measurement;
- •NYHA class III-IV heart failure, or hospitalization for chronic heart failure exacerbation within the past 6 months;
- •Severe valvular diseases; Potential for surgery or percutaneous valve replacement within the study period;
- •Dilated cardiomyopathy, hypertrophic cardiomyopathy, rheumatic heart disease, or congenital heart disease;
- •Other severe diseases that may affect participant enrollment or survival, such as malignancy or acquired immunodeficiency syndrome (AIDS);
- •Cognitive impairment or severe neuropsychiatric comorbidities that render the patient incapable of providing informed consent;
- •Participants preparing for or under pregnancy and/or lactation;
- •Frequent night-shift work, with primary working hours during nighttime (e.g., 8:00 PM to 8:00 AM);
- •Other conditions deemed inappropriate for participation by the investigators.
研究者
Jun Cai
Director, Head of Hypertension Center, Principal Investigator, Clinical Professor
Beijing Anzhen Hospital
研究点 (16)
Loading locations...
相似试验
尚未招募
不适用
Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPDNCT07393685Tianjin Medical University300
尚未招募
2/3 期
this is a study to find out how well the less commonly used homoeopathic medicines work in hypertension (high blood pressure)CTRI/2026/02/103501S S Agrawal Homoeopathic Medical College and General Hospital80
尚未招募
不适用
Huangjing Yangji Formula Combined With Resistance Training for SarcopeniaNCT07321535Wangjing Hospital, China Academy of Chinese Medical Sciences106
尚未招募
不适用
Trial of Herbal Syrup in HypertensionCTRI/2024/09/073923Defence Institute of Bio-Energy Research60
尚未招募
不适用
An Observational Study to Assess Ayurvedic Pathogenesis of HypertensionCTRI/2025/02/081117Dr Suyog Jawake201